The University of Oxford has stopped administering doses of the COVID-19 vaccine developed with AstraZeneca PLC AZN,
AZN,
in a small study in the UK that aims to assess its safety and efficacy in children and adolescents, to await more information about the rare blood clotting problems that were found in a small group of adults who received it, reported the Wall Street Journal on Tuesday. The trial began in mid-February and involves more than 200 youths aged 6 to 17, the newspaper said. He quoted an Oxford spokesman as saying the test found no safety problems, but that broader concerns and a review of the vaccine by regulators in the UK and the European Union were behind the change. The European Medicines Agency said it hopes to update the public on its investigation of the blood clotting problem later this week.
